These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35514050)

  • 41. The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana.
    Maseng MJ; Tawe L; Thami PK; Moyo S; Kasvosve I; Novitsky V; Essex M; Russo G; Gaseitsiwe S; Paganotti GM
    Medicine (Baltimore); 2022 Apr; 101(17):e29066. PubMed ID: 35512066
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.
    Rotger M; Colombo S; Furrer H; Bleiber G; Buclin T; Lee BL; Keiser O; Biollaz J; Décosterd L; Telenti A;
    Pharmacogenet Genomics; 2005 Jan; 15(1):1-5. PubMed ID: 15864119
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
    Maganda BA; Minzi OM; Ngaimisi E; Kamuhabwa AA; Aklillu E
    Pharmacogenomics J; 2016 Feb; 16(1):88-95. PubMed ID: 25963334
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Constitutive androstane receptor and pregnane X receptor genotype influence efavirenz plasma concentration and CYP2B6 enzyme activity.
    Petros Z; Habtewold A; Makonnen E; Aklillu E
    Sci Rep; 2022 Jun; 12(1):9698. PubMed ID: 35690682
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
    Mukonzo JK; Okwera A; Nakasujja N; Luzze H; Sebuwufu D; Ogwal-Okeng J; Waako P; Gustafsson LL; Aklillu E
    BMC Infect Dis; 2013 Jun; 13():261. PubMed ID: 23734829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.
    Gallien S; Journot V; Loriot MA; Sauvageon H; Morlat P; Reynes J; Reliquet V; Chêne G; Molina JM;
    HIV Med; 2017 Sep; 18(8):537-545. PubMed ID: 28145050
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.
    Abdelhady AM; Desta Z; Jiang F; Yeo CW; Shin JG; Overholser BR
    J Clin Pharmacol; 2014 Jan; 54(1):87-96. PubMed ID: 24142869
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.
    Saitoh A; Fletcher CV; Brundage R; Alvero C; Fenton T; Hsia K; Spector SA
    J Acquir Immune Defic Syndr; 2007 Jul; 45(3):280-5. PubMed ID: 17356468
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meta-analysis of the associations of CYP2B6-516G>T polymorphisms with efavirenz-induced central nervous system side effects and virological outcome in HIV-infected adults.
    Cheng L; Wang Y; Li X; Feng W; Weng B; Yuan Q; Xia P; Sun F
    Pharmacogenomics J; 2020 Apr; 20(2):246-259. PubMed ID: 31636355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism.
    Sukasem C; Manosuthi W; Koomdee N; Santon S; Jantararoungtong T; Prommas S; Chamnanphol M; Puangpetch A; Sungkanuparph S
    Infection; 2014 Jun; 42(3):469-74. PubMed ID: 24293076
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives.
    Haas DW; Cramer YS; Godfrey C; Rosenkranz SL; Aweeka F; Berzins B; Coombs R; Coughlin K; Moran LE; Gingrich D; Zorrilla CD; Baker P; Cohn SE; Scarsi KK;
    Pharmacogenet Genomics; 2020 Apr; 30(3):45-53. PubMed ID: 32106141
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
    Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J
    J Clin Pharmacol; 2016 Dec; 56(12):1538-1549. PubMed ID: 27125860
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
    Gatanaga H; Hayashida T; Tsuchiya K; Yoshino M; Kuwahara T; Tsukada H; Fujimoto K; Sato I; Ueda M; Horiba M; Hamaguchi M; Yamamoto M; Takata N; Kimura A; Koike T; Gejyo F; Matsushita S; Shirasaka T; Kimura S; Oka S
    Clin Infect Dis; 2007 Nov; 45(9):1230-7. PubMed ID: 17918089
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
    di Iulio J; Fayet A; Arab-Alameddine M; Rotger M; Lubomirov R; Cavassini M; Furrer H; Günthard HF; Colombo S; Csajka C; Eap CB; Decosterd LA; Telenti A;
    Pharmacogenet Genomics; 2009 Apr; 19(4):300-9. PubMed ID: 19238117
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influence of CYP2B6 activity score on the pharmacokinetics and safety of single dose efavirenz in healthy volunteers.
    Zubiaur P; Saiz-Rodríguez M; Ochoa D; Belmonte C; Román M; Mejía G; Martín-Vilchez S; Abad-Santos F
    Pharmacogenomics J; 2020 Apr; 20(2):235-245. PubMed ID: 31628422
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients.
    Ramachandran G; Kumar AK; Ponnuraja C; Ramesh K; Rajesh L; Chandrasekharan C; Swaminathan S
    Indian J Med Res; 2013 Dec; 138(6):955-61. PubMed ID: 24521642
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.
    Mukonzo JK; Röshammar D; Waako P; Andersson M; Fukasawa T; Milani L; Svensson JO; Ogwal-Okeng J; Gustafsson LL; Aklillu E
    Br J Clin Pharmacol; 2009 Nov; 68(5):690-9. PubMed ID: 19916993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
    Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.
    Mhandire D; Lacerda M; Castel S; Mhandire K; Zhou D; Swart M; Shamu T; Smith P; Musingwini T; Wiesner L; Stray-Pedersen B; Dandara C
    OMICS; 2015 Sep; 19(9):553-62. PubMed ID: 26348712
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediction of the exposure to a 400-mg daily dose of efavirenz in pregnancy: is this dose adequate in extensive metabolisers of CYP2B6?
    Chetty M; Danckwerts MP; Julsing A
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1143-1150. PubMed ID: 32377759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.